Advances in the understanding and management of primary myelofibrosis

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 665-671

  Cervantes, Francisco ^a   Pereira, Arturo ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

JAK2 inhibitors; janus kinase 2; primary myelofibrosis; prognosis; treatment

Indexed keywords

JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LESTAURTINIB; RUXOLITINIB; TG 101384; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; DRUG EFFICACY; EZH2 GENE; GENE; GENE MUTATION; HUMAN; MYELOFIBROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SPLENOMEGALY; TET2 GENE; THROMBOSIS; TREATMENT PLANNING;

ANIMALS; HUMANS; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS;

EID: 80054122729     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834bb83f     Document Type: Review

References (45)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-951.
2. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 2007; 31:737-740. (Pubitemid 46855906)
3. Abdel-Wahab O. Genetics of the myeloproliferative neoplasms. Curr Opin Hematol 2011; 18:117-123.
4. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24:1128-1138.
5. Santos FPS, Verstovsek S. JAK2 inhibitors: what's the true potential? Blood Rev 2011; 25:53-63.
6. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wildtype Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111:3931-3940.
7. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110:4030-4036. (Pubitemid 350248459)
8. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22:756-761. (Pubitemid 351559282)
9. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009; 114:1477-1483.
10. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3:e270.
11. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112:141-149.
12. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360:2289-2301.
13. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23:905-911.
14. Beer PA, Delhommeau F, LeCoué dic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010; 115:2891-2900.
15. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42:722-726.
16. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41:446-449.
17. Olcaydu D, Harutyunyan A, Jä ger R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41:450-454.
18. Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms. Nat Genet 2009; 41:455-459.
19. Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010; 24:105-109.
20. Guglielmelli P, Biamonte F, Spolverini A, et al. Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia 2010; 24:1533-1537.
21. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113:2895-2901.
22. Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115:778-782.
23. Elliott MA, Pardanani A, Lasho TL, et al. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica 2010; 95:1788-1791.
24. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88:1013-1018. (Pubitemid 26333326)
25. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWGMRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115:1703-1708.
26. Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion- dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica 2010; 96:167-170.
27. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29:392-397.
28. Morel P, Duhamel A, Hivert B, et al. Identification during the follow-up of timedependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood 2010; 115:4350-4355.
29. Vaidya R, Caramazza D, Begna KH, et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood 2011; 117:5612-5615.
30. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29:1356-1363.
31. Barbui T, Barosi G, Birgegard G, Cervantes F, et al. Philadelphia- negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29:761-770.
32. Tefferi A. How I treat myelofibrosis. Blood 2011; 117:3494-3504.
33. Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010; 116:4436-4438.
34. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009; 27:4563-4569.
35. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis with anemia. Leukemia 2011; 25:301-304.
36. Martínez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010; 89:1233-1237.
37. Krö ger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114:5264-5270.
38. Karen K, Ballen KK, Shrestha S, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16:358-367.
39. Robin M, Tabrizi R, Mohty M, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Socié té Française de Greffe de Moelle et de Thé rapie Cellulaire (SFGM-TC). Br J Haematol 2011; 152:331-339.
40. Abelsson J, Merup M, Birgega rd G, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant 2011. [Epub ahead of print]
41. Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol 2011; 18:105-110.
42. Pardanani A, Vannucchi AM, Passamonti F. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011; 25:218-225.
43. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363:1117-1127.
44. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29:789-796.
45. Santos FPS, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or postpolycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010; 115:1131-1136.